Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of These 10 Stocks Are Making Big Moves. Recursion Pharmaceuticals ...

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Wall Street’s main indices all finished in the red, led by the Dow Jones with 0.94 percent, followed by the Nasdaq with 0.92 ...